Lactocore is a preclinical stage company at the cutting edge of computer-aided drug discovery. There is a tremendous unmet need for new drugs with novel mechanisms of action and drastically improved safety profiles in the areas of depression and anxiety. Lactocore is focused on fast and efficient early stage development to generate high quality candidates suitable for partnering with bigger pharmaceutical companies. It is currently in the midst of a $10M round with $3M in to bring leading asset to the completion of preclinical and Phase I clinical studies, and to advance other candidates.
What you will learn from the webinar: Why novel drugs against depression and anxiety represent an attractive investment opportunity, and how Lactocore is uniquely positioned to capitalize on this new wave of interest to psychiatry indications.
